Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on September 7, 2005
J Am Soc Nephrol 16: 2830-2832, 2005
© 2005 American Society of Nephrology
doi: 10.1681/ASN.2005080841

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2005080841v1
16/10/2830    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kretzler, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kretzler, M.

Editorials

Role of Podocytes in Focal Sclerosis: Defining the Point of No Return

Matthias Kretzler

Nephrology Center, Medizinische Poliklinik, University of Munich, Munich, Germany

Address correspondence to: Dr. Matthias Kretzler, Nephrology Center, Medizinische Poliklinik, Schillerstrasse 42, D-80336 Munich, Germany. Phone: +49-89-2180-75845; FAX: +49-89-2180-75860; E-mail: matthias.kretzler{at}med.uni-muenchen.de


    Introduction
 Top
 Introduction
 Is There a Causal...
 References
 
Podocyte dysfunction is linked to progressive glomerular filtration barrier failure and glomerulosclerosis. A detailed sequence of structural alterations is now used to define three general modes of podocyte damage, highlighting degenerative, inflammatory, or dysregulative pathways to glomerulosclerosis (1).

In this issue of JASN, three reports offer novel insights into the causal relationship between podocyte damage and glomerulosclerosis and define specific markers that identify the "point of no return" in glomerular filtration barrier failure. The authors have focused on the following questions:


    Is There a Causal Relationship between Lack of Podocytes and Progressive Glomerulosclerosis?
 Top
 Introduction
 Is There a Causal...
 References
 
Over the last 15 yr, much evidence has been accumulated correlating podocyte loss with progressive glomerulosclerosis (2). To date, direct evidence that podocyte depletion is sufficient to cause glomerulosclerosis was lacking. Transgene technology was used to experimentally address this question. Matsusaka et al. selectively depleted podocytes in adult mice transgenic for the human CD25 with an anti-CD25 immunotoxin, resulting in a dose dependent induction of glomerulosclerosis (3). Using the diphtheria toxin in rats with podocytes transgenic for the human diphtheria toxin receptor, Wharram et al. were able to titrate the administration of toxin to induce defined levels of podocyte depletion (4). The rats used in this study showed dose-dependent structural alterations with all of the characteristic features of focal segmental glomerulosclerosis. Both reports provide experimental evidence for the essential role of podocytes in glomerular function.

Does the Degree of Podocyte Loss Correlate with Defined Stages of Glomerular Damage?
Wharram et al. show that a depletion of <20% of podocytes caused transient proteinuria and mesangial expansion, loss of 20 to 40% podocytes resulted in persistent proteinuria and focal glomerulosclerosis, but no progressive decline in renal function, and >40% podocyte loss caused progressive glomerular failure.

In the second study reported by the Wiggins group, a different approach led to comparable conclusions (5). Fischer 344 rats show spontaneous, aging-associated glomerulosclerosis. Surprisingly, quantification of glomerular cells and volumes in these rats was not able to show an age-related loss of podocytes, but a considerable glomerular hypertrophy with aging.

Why Would Glomerular Hypertrophy Cause a Similar Phenotype as Seen with Podocyte Depletion?
The key aspect of podocyte function is the maintenance of a defined surface of the glomerular filtration area. A loss of podocytes or an increase in filtration area to be served (with stable podocyte number) should result in increased demands on the remaining podocytes. In the study of aging rats, glomerular volume appears to have outgrown podocyte hypertrophic capacity at the 24th month of life. This lead to a 60% decrease in podocyte per glomerular volume (also referred to as podocyte density) (5), comparable to the reduction in podocyte density causing progressive glomerular damage shown in the depletion study (4). As calorie restriction can prevent age-related alteration in Fischer 344 rats, aging lean rats were evaluated for their glomerular phenotype. These animals showed an intact filtration barrier. In keeping with the concept of a critical threshold of podocyte depletion, these rats had decreased their podocyte density only by 30%. As predicted from the depletion study (4), the lean rats did not show parameters of podocyte stress or glomerulosclerosis (5).

Are There Specific Diagnostic Parameters That Can Be Used to Define the Critical Stages of Podocyte Stress in Glomerular Disease?
Defining a threshold of podocyte depletion/stress-causing progressive glomerular disease would have far-reaching clinical consequences. How do these findings in rat models compare with available human studies? Correlating podocyte numbers with the degree of glomerular damage, comparable thresholds of podocyte density had been obtained in human diabetic nephropathy, with microalbuminuria seen with 20% and clinical nephropathy with 40% podocyte loss (6). Similar results were obtained for podocyte damage in IgA nephritis (7).

Should we start to determine podocyte density in human renal biopsies to assess the level of podocyte stress? Aside from the technical issues that would have to be overcome, a major limitation of this approach would be the considerable number of glomeruli required for robust morphometric studies. An alternative strategy is the noninvasive monitoring of loss of podocytes in the urine, an approach that is currently being evaluated for its predictive power (810). Urinary podocyte levels could serve as a general marker of ongoing glomerular damage, but could not in itself be used as an estimate of the functional reserve maintained in the individual patient.

Wiggins et al. used genome-wide expression profiles in the aging rats to screen for markers of defined levels of podocyte stress (5). A repression of molecules intimately linked to podocyte function (nephrin, WT1, GLEPP1) was seen at onset of progressive proteinuria in the decompensation stage. Can comparable markers be identified in human glomerular aging and disease? Initial data from a cohort of pretransplant biopsies taken from living donors shows a similar result with a significant negative correlation between donor age and glomerular expression of podocyte-specific markers (Lemley and Kretzler, unpublished observation). In preliminary studies of human glomerular disease and aging, the desmin to nephrin ratio was not found to correlate as clearly with podocyte stress as in the aging rats (author’s unpublished observation). The hope is that large-scale mRNA expression screening approaches currently underway in human glomerular disease will yield similar clear-cut markers for human podocyte stress (11). To identify molecular parameters of glomerulosclerosis, an additional approach has been added to our toolbox. Using the 5/6 nephrectomy rat model, Xu et al. (12) were able to generate reproducible proteomic signatures from laser-microdissected glomerular cross-sections. The signatures obtained not only separated sclerotic from normal glomeruli, but also gave a specific pattern for presclerotic glomeruli. In a second step, thymosin {beta}4 was identified to contribute to the differential proteomic signature and can now be evaluated as an early marker of glomerulosclerosis.

Can We Prevent or Even Treat Decreased Podocyte Density and Stress?
If glomerular sclerosis is indeed, as stated by Wiggins, a cell-depletion disease, could it be a target for the emerging field of regenerative medicine? Considering the unique anatomical and functional environment of the podocyte, it appears to be exquisitely difficult to reload an actively filtering glomerulus with podocytes integrated into the complex three-dimensional network of interdigitating foot processes. Introducing proliferative podocyte precursor cells into a damaged glomerulus might have disastrous consequences, as it could lead to scenarios resembling podocyte proliferation in collapsing glomerulopathy (1).

As podocyte density is defined not only by podocyte number, but also by glomerular surface area, targeting glomerular hypertrophy is the alternative approach and has proven to be an effective therapeutic strategy for progressive glomerular disease. In this context, the prevention of glomerulosclerosis by dietary restriction in the aging Fischer rats reported by Wiggins is remarkable (5). Observational studies have shown a close correlation of obesity with progression of renal disease (13), most strikingly in humans with reduced renal mass (14). As addressed also by several recent manuscripts and editorials in JASN (15,16), aggressive management of this risk factor is warranted with an aging, obese population at the doorsteps of our clinics.

The study of podocytes in glomerular filtration barrier failure has come of age. The experimental insight gained by combining transgene technology with genomic and proteomic tools is starting to provide the molecular basis for disease stage classification, diagnostic parameters for rapid assessment of therapies, and paths to open new therapeutic avenues.


    Footnotes
 
Published online ahead of print. Publication date available at www.jasn.org.


    References
 Top
 Introduction
 Is There a Causal...
 References
 

  1. Kriz W, LeHir M: Pathways to nephron loss starting from glomerular diseases—Insights from animal models. Kidney Int 67 : 404 –419, 2005[CrossRef][Medline]
  2. Pavenstadt H, Kriz W, Kretzler M: Cell biology of the glomerular podocyte. Physiol Rev 83 : 253 –307, 2003[Abstract/Free Full Text]
  3. Matsusaka T, Xin J, Niwa S, Kobayashi K, Akatsuka A, Hashizume H, Wang QC, Pastan I, Fogo, AB, Ichikawa I: Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 16 : 1013 –1023, 2005[Abstract/Free Full Text]
  4. Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC: Podocyte depletion causes glomerulosclerosis: Diphteria toxin-induced podocyte depletion in rats expressing the human diphteria toxin receptor transgene. J Am Soc Nephrol 16 : 2941 –2952, 2005[Abstract/Free Full Text]
  5. Wiggins JE, Goyal M, Sanden SK, Wharram BL, Shedden KA, Misek DE, Kuick RD, Wiggins RC: Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: Prevention by calorie restriction. J Am Soc Nephrol 16 : 2953 –2966, 2005[Abstract/Free Full Text]
  6. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun, L, Meyer TW: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99 : 342 –348, 1997[Medline]
  7. Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, Myers BD: Podocytopenia and disease severity in IgA nephropathy. Kidney Int 61 : 1475 –1485, 2002[CrossRef][Medline]
  8. Hara M, Yanagihara T, Takada T, Itoh M, Matsuno M, Yamamoto, T, Kihara I: Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol 18 : 35 –41, 1998[CrossRef][Medline]
  9. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV: Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 285 : F40 –F48, 2003[Abstract/Free Full Text]
  10. Yu D, Petermann A, Kunter U, Rong S, Shankland, SJ, Floege J: Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 16 : 1733 –1741, 2005[Abstract/Free Full Text]
  11. Henger A, Schmid H, Kretzler M: Gene expression analysis of human renal biopsies: Recent developments towards molecular diagnosis of kidney disease. Curr Opin Nephrol Hypertens 13 : 313 –318, 2004[Medline]
  12. Xu BJ, Shyr Y, Liang X, Ma LJ, Donnert EM, Roberts JD, Zhang X, Kon V, Brown NJ, Caprioli RM, Fogo AB: Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol 16 : 2967 –2975, 2005[Abstract/Free Full Text]
  13. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S: Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 65 : 1870 –1876, 2004[CrossRef][Medline]
  14. Gonzalez E, Gutierrez E, Morales E, Hernandez E, Andres A, Bello I, Diaz-Gonzalez R, Leiva O, Praga M: Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int 68 : 263 –270, 2005[CrossRef][Medline]
  15. Kurella M, Lo JC, Chertow GM: Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16 : 2134 –2140, 2005[Abstract/Free Full Text]
  16. Sedor JR, Schelling JR: Association of metabolic syndrome in nondiabetic patients with increased risk for chronic kidney disease: The fat lady sings. J Am Soc Nephrol 16 : 1880 –1882, 2005[Free Full Text]



This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
S. Oba, M. Hino, and T. Fujita
Adrenomedullin protects against oxidative stress-induced podocyte injury as an endogenous antioxidant
Nephrol. Dial. Transplant., February 1, 2008; 23(2): 510 - 517.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
K. V. Lemley, R. A. Lafayette, G. Derby, K. L. Blouch, L. Anderson, B. Efron, and B. D. Myers
Prediction of early progression in recently diagnosed IgA nephropathy
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 213 - 222.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Barton, J. J. Mullins, M. A. Bailey, and M. Kretzler
Role of Endothelin Receptors for Renal Protection and Survival in Hypertension: Waiting for Clinical Trials
Hypertension, November 1, 2006; 48(5): 834 - 837.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2005080841v1
16/10/2830    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kretzler, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kretzler, M.


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP